-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JAB-3312 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JAB-3312 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JAB-3312 in Solid Tumor Drug Details: JAB-3312 is under development for...
-
Product Insights
Anaphylaxis – Drugs In Development, 2023
Global Markets Direct’s, ‘Anaphylaxis - Drugs In Development, 2023’, provides an overview of the Anaphylaxis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaphylaxis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Acute Opioid Overdosage – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Opioid Overdosage - Drugs In Development, 2023’, provides an overview of the Acute Opioid Overdosage pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Opioid Overdosage, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Opium (Opioid) Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Opium (Opioid) Addiction - Drugs In Development, 2023’, provides an overview of the Opium (Opioid) Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nalmefene in Acute Opioid Overdosage
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nalmefene in Acute Opioid Overdosage report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nalmefene in Acute Opioid Overdosage Drug Details: Nalmefene (OX-125) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naloxone in Acute Opioid Overdosage
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naloxone in Acute Opioid Overdosage report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ETH-155008 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ETH-155008 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ETH-155008 in Refractory Acute Myeloid Leukemia Drug Details:ETH-155008 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BRESCAP in Acute Renal Failure (ARF) (Acute Kidney Injury)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BRESCAP in Acute Renal Failure (ARF) (Acute Kidney Injury) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BRESCAP in Acute Renal Failure (ARF) (Acute Kidney...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ketorolac in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ketorolac in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Ketorolac in PainDrug Details:Ketorolac is under development for the treatment of moderate to moderately...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APVO-436 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APVO-436 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.APVO-436 in Relapsed Acute Myeloid LeukemiaDrug Details:APVO-436 is under development for...